Somewhat Favorable News Coverage Somewhat Unlikely to Impact Edge Therapeutics (EDGE) Stock Price

Media headlines about Edge Therapeutics (NASDAQ:EDGE) have trended somewhat positive on Friday, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Edge Therapeutics earned a media sentiment score of 0.04 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.1253441227601 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

How to Become a New Pot Stock Millionaire

Shares of NASDAQ EDGE traded down $0.02 during mid-day trading on Friday, hitting $1.10. 1,108,575 shares of the stock traded hands, compared to its average volume of 1,130,690. The company has a quick ratio of 6.92, a current ratio of 6.92 and a debt-to-equity ratio of 0.28. Edge Therapeutics has a 52 week low of $0.95 and a 52 week high of $17.77. The firm has a market capitalization of $33.34, a PE ratio of -0.66 and a beta of 3.98.

Edge Therapeutics (NASDAQ:EDGE) last released its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.45) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.02).

EDGE has been the topic of several research reports. Credit Suisse Group lowered Edge Therapeutics from an “outperform” rating to an “underperform” rating and set a $17.00 price target on the stock. in a research report on Thursday, March 29th. BidaskClub upgraded Edge Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, March 7th. JMP Securities lowered Edge Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, March 28th. Finally, Zacks Investment Research lowered Edge Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd.

In other Edge Therapeutics news, CEO Brian A. Leuthner sold 2,500 shares of Edge Therapeutics stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $14.81, for a total transaction of $37,025.00. Following the completion of the transaction, the chief executive officer now owns 72,736 shares in the company, valued at $1,077,220.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider R. Loch Macdonald sold 5,000 shares of Edge Therapeutics stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $13.75, for a total value of $68,750.00. Following the transaction, the insider now owns 590,602 shares of the company’s stock, valued at approximately $8,120,777.50. The disclosure for this sale can be found here. Insiders have sold 17,500 shares of company stock worth $257,800 over the last 90 days. 36.19% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This piece was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at

Edge Therapeutics Company Profile

Edge Therapeutics, Inc, a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage.

Insider Buying and Selling by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply